Status:
COMPLETED
USF Hemostasis: USage of HemCon for Femoral Hemostasis After Percutaneous Procedures
Lead Sponsor:
Meir Medical Center
Conditions:
Coronary Angiography
Eligibility:
All Genders
18-80 years
Phase:
PHASE4
Brief Summary
USF Hemostasis - USage of HemCon for Femoral Hemostasis after Percutaneous Procedures. A Comparative Open Label Study The purpose of this trial is to test HemCon pad after diagnostic percutaneous coro...
Detailed Description
USF Hemostasis USage of HemCon for Femoral Hemostasis after Percutaneous Procedures A Comparative Open Label Study Introduction After completion of angiography performed via the femoral artery, hemost...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Age 18-80 years old
- Signing an informed consent
- Percutaneous coronary angiography with a 6 french sheath via the femoral artery
- Post catheterization non-invasive systolic blood pressure 150 mm Hg
- Exclusion criteria:
- STEMI
- Patients who received IIb-IIIa antagonists before or during angiography.
- Patients who received more than 2500u IV Heparin or more than 0.5 mg/kg LMWH within 8 hours before the procedure.
- Known bleeding tendency, disturbed clotting system or platelet function
- Evidence of bleeding or hematoma at the access site prior to sheath removal.
Exclusion
Key Trial Info
Start Date :
January 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2011
Estimated Enrollment :
278 Patients enrolled
Trial Details
Trial ID
NCT00716365
Start Date
January 1 2008
End Date
August 1 2011
Last Update
August 16 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Meir Medical Center
Kfar Saba, Israel, 44281